Veterinary Auto-Immune Therapeutics Market
Veterinary Auto-immune Therapeutics are Gaining Strength. Know the Key Highlights
Veterinary auto-immune Therapeutics Market by Therapy Type, Disease Indication, Animal Type, Distribution Channel & Region | Forecast 2022 to 2032.
Veterinary Auto-Immune Therapeutics Market Outlook (2022 to 2032)
The global veterinary auto-immune therapeutics market is projected to be appraised at US$ 69010.77293 million by 2032, up from US$ 41087.71686 million in 2022, advancing at a CAGR of 5.3% from 2022 to 2032.
The adoption of veterinary auto-immune therapeutics is on the surge as several new ways of treating autoimmune diseases in animals using various drugs and other therapies like surgeries and stem cell therapies are evolving worldwide.
The demand for these drugs also rises as used to reduce the symptoms associated with the specific autoimmune disease. Furthermore, auto-immune disease treatment is gaining more attention owing to an increased threat of zoonotic disease transfer among humans, in turn positively impacting the veterinary auto-immune therapeutics market outlook.
Hence, the growing incidence of zoonotic disease transfer is changing business operations of the animal healthcare industry as emergency care.
|
Report Attribute |
Details |
|
Veterinary auto-immune therapeutics Market Value (2022) |
US$ 41087.71686 Million |
|
Veterinary auto-immune therapeutics Market Anticipated Forecast Value (2032) |
US$ 69010.77293 Million |
|
Veterinary auto-immune therapeutics Market Projected Growth Rate (2022 to 2032) |
5.3% |
The veterinary auto-immune therapeutics market growth is fuelled by veterinary hospitals as they are offering a wide range of therapeutic services for companion animals. An increase in the prevalence of autoimmune illness and a rise in Research and Development efforts to provide the best possible treatments in tandem with a surge in the use of therapeutics for the condition are also anticipated to contribute to the market growth in coming years.
Moreover, the market is expanded by the rise in autoimmune disease incidence and early illness detection, and the recent introduction of cutting-edge therapies during the forecast period. A significant number of late-stage pipeline medications are also present, including tocilizumab, certolizumab, baricitinib, etanercept, secukinumab, elotuzumab, abatacept, PF-06438179, apremilast, golimumab, certolizumab, ustekinumab, tofacitinib, and others.
The increasing transfer of zoonotic diseases among immunosuppressed patients is a prime factor responsible for the rising awareness of the auto-immune disease among companion animals.
Customize this Report
Let us know your requirement to get
100% FREE customization
What Are The Key Veterinary Auto-Immune Therapeutics Market?
The high threat of HIV transfer from the animal source to a person with suppressed immunity, and the transfer of allergic components from companion animals to family members are also spiking the demand for veterinary auto-immune therapeutics.
The growing incidence of autoimmune diseases in livestock animals has decreased the quality of meat consumed especially in pharmaceutical manufacturing. Moreover, the focus on livestock health among African countries which are the main exporters of livestock is further surging the demand for autoimmune disease therapy.
However, limited therapy options for animals in developing countries and a lack of awareness are hindering the growth of the veterinary auto-immune therapeutics market.
Why Is North America Likely To Lead The Veterinary Auto-Immune Therapeutics Market?
Due to numerous government-sponsored programs that promote these diagnostic tests, North America holds the largest market share in the world for the diagnosis of animal auto-immune diseases accounting for 29% in 2022. The increased demand for all healthcare improvements for animal welfare is a result of the region's increased meat consumption.
There is a huge knowledge of the effects and impacts of auto-immune disorders thanks to their prevalence, in turn expanding the veterinary auto-immune therapeutics market size.
Sabyasachi Ghosh
Principal Consultant
Talk to Analyst
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat Is The Growth Outlook For The Europe Veterinary Auto-Immune Therapeutics Market?
Europe is likely to get hold of the veterinary auto-immune therapeutics market share of 22.9% in 2022. The main factor driving rising utilization rates is the increased awareness of animal autoimmune diseases brought on by programs in research, support, advocacy, and education.
The European Commission is pursuing a number of initiatives to rise public knowledge of the factors that may contribute to the onset of animal auto-immune diseases, thereby spurring the adoption of such therapeutics.
How Is The Start-up Ecosystem In The Veterinary Auto-Immune Therapeutics Market?
A Med City biotech company received more than $330,000 in federal money to explore gene therapy for dogs and possibly people in the future. The National Institutes of Health has given a $337,443 Phase I Small Business Innovation Research grant to Life Engine Animal Health, or LEAH Labs, led by CEO and co-founder Dr. Wes Wierson.
With assistance from the Mayo Clinic, Wierson developed gene editing methods that are used by LEAH Labs. The Mayo Clinic granted a license to LEAH Labs for the study. Downtown Rochester is where LEAH Labs is headquartered.
In the second quarter of 2022, pilot tests for the start-up's first product, a CAR-T cell therapy for cancerous dogs, are anticipated to begin. The objective is to develop a treatment for canine B cell lymphoma malignancy. An estimated 300,000 canines every year succumb to that form of cancer, which is analogous to Non-lymphoma Hodgkin's in people.
Become a MarketNgage Insider
A unified Market Research Subscription Platform, built for today's disparate research needs.
What Is The Competition Landscape In The Veterinary Auto-Immune Therapeutics Market?
Market players are employing various organic and inorganic strategies including mergers & acquisitions, partnerships, collaborations, etc. in order to consolidate their position in the veterinary auto-immune therapeutics market.
A few of the recent developments in the veterinary auto-immune therapeutics market are:
- Leading provider of life science solutions QIAGEN N.V. was purchased by Thermo Fisher Scientific Inc. They operate in 25 nations and offer diagnostic solutions for all geographical areas.
- A unique blood test that displays the risk index of autoimmune illnesses was introduced by Progentec. In 12 weeks, it can evaluate the propensity for systemic lupus erythematosus.
Key players
- Aratana Therapeutics Inc.
- Pfizer Inc.
- Vet-Stem, Inc.
- Ambrx Inc.
- Taconic Biosciences, Inc.
- JBS United
- Virbac
- Eli Lilly and Company
- Jaguar Animal Health Inc.
Report Scope
|
Report Attribute |
Details |
|
Growth Rate |
CAGR of 5.3% from 2022 to 2032 |
|
Base Year for Estimation |
2021 |
|
Historical Data |
2016 to 2021 |
|
Forecast Period |
2022 to 2032 |
|
Quantitative Units |
Revenue in USD Million and CAGR from 2022 to 2032 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled In The Veterinary Auto-Immune Therapeutics Market Survey
By Therapy Type:
- Corticosteroids, Azathioprine
- Cyclosporine
- Mycophenolate
- Leflunomide
- Cyclophosphamide
- Levothyroxine
- Folic Acid
- Hydroxychloroquine
- Chloroquine
By Disease Indication:
- Hypothyroidism
- Pemphigus Disease
- Canine Lupus
- Auto-Immune Hemolytic Anemia
- Bullous Pemphigoid
- Discoid Lupus Erythematosus (DLE)
- Immune-related arthritis
- Others
By Animal Type:
- Companion Animal
- Dogs
- Cats
- Horse
- Live Stock Animal
- Cattle
- Swine
- Poultry
- Fish
- Sheep
By Distribution Channel:
- Veterinary Hospitals
- Veterinary Clinics
By Region:
- North America
- Latin America
- The Asia Pacific
- Middle East and Africa
- Europe
Frequently Asked Questions
What is the Growth Outlook for the Veterinary auto-immune therapeutics Market?
The veterinary auto-immune therapeutics market is projected to move ahead with a 5.3% CAGR (2022 to 2032).
Which Region Holds a Major Veterinary auto-immune therapeutics Market Share?
North America is anticipated to hold a major veterinary auto-immune therapeutics market share.
What is the Future of the Veterinary auto-immune therapeutics Market?
The veterinary auto-immune therapeutics market is anticipated account for US$ 69010.77293 million by 2032.
Table of Content
1. Executive Summary | Veterinary Auto-Immune Therapeutics Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032 4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2021 4.2. Current and Future Market Size Value (US$ Million) Projections, 2022 to 2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Therapy Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Therapy Type, 2017 to 2021 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy Type, 2022 to 2032 5.3.1. Corticosteroids 5.3.2. Azathioprine 5.3.3. Cyclosporine 5.3.4. Mycophenolate 5.3.5. Leflunomide 5.3.6. Cyclophosphamide 5.3.7. Levothyroxine 5.3.8. Folic Acid 5.3.9. Hydroxychloroquine 5.3.10. Chloroquine 5.4. Y-o-Y Growth Trend Analysis By Therapy Type, 2017 to 2021 5.5. Absolute $ Opportunity Analysis By Therapy Type, 2022 to 2032 6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Disease Indication 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Disease Indication, 2017 to 2021 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Indication, 2022 to 2032 6.3.1. Hypothyroidism 6.3.2. Pemphigus Disease 6.3.3. Canine Lupus 6.3.4. Auto-Immune Hemolytic Anemia 6.3.5. Bullous Pemphigoid 6.3.6. Discoid Lupus Erythematosus (DLE) 6.3.7. Immune-related arthritis 6.3.8. Others 6.4. Y-o-Y Growth Trend Analysis By Disease Indication, 2017 to 2021 6.5. Absolute $ Opportunity Analysis By Disease Indication, 2022 to 2032 7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Animal Type 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Animal Type, 2017 to 2021 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Animal Type, 2022 to 2032 7.3.1. Companion Animal 7.3.2. Dogs 7.3.3. Cats 7.3.4. Horse 7.3.5. Live Stock Animal 7.3.6. Cattle 7.3.7. Swine 7.3.8. Poultry 7.3.9. Fish 7.3.10. Sheep 7.4. Y-o-Y Growth Trend Analysis By Animal Type, 2017 to 2021 7.5. Absolute $ Opportunity Analysis By Animal Type, 2022 to 2032 8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Distribution Channel Type 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel Type, 2017 to 2021 8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel Type, 2022 to 2032 8.3.1. Veterinary Hospitals 8.3.2. Veterinary Clinics 8.4. Y-o-Y Growth Trend Analysis By Distribution Channel Type, 2017 to 2021 8.5. Absolute $ Opportunity Analysis By Distribution Channel Type, 2022 to 2032 9. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2021 9.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2022 to 2032 9.3.1. North America 9.3.2. Latin America 9.3.3. Europe 9.3.4. Asia Pacific 9.3.5. Middle East and Africa 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 10.2.1. By Country 10.2.1.1. United States of America 10.2.1.2. Canada 10.2.2. By Therapy Type 10.2.3. By Disease Indication 10.2.4. By Animal Type 10.2.5. By Distribution Channel Type 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Therapy Type 10.3.3. By Disease Indication 10.3.4. By Animal Type 10.3.5. By Distribution Channel Type 10.4. Key Takeaways 11. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Therapy Type 11.2.3. By Disease Indication 11.2.4. By Animal Type 11.2.5. By Distribution Channel Type 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Therapy Type 11.3.3. By Disease Indication 11.3.4. By Animal Type 11.3.5. By Distribution Channel Type 11.4. Key Takeaways 12. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. United Kingdom 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Europe 12.2.2. By Therapy Type 12.2.3. By Disease Indication 12.2.4. By Animal Type 12.2.5. By Distribution Channel Type 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Therapy Type 12.3.3. By Disease Indication 12.3.4. By Animal Type 12.3.5. By Distribution Channel Type 12.4. Key Takeaways 13. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.1.4. Malaysia 13.2.1.5. Singapore 13.2.1.6. Australia 13.2.1.7. Rest of Asia Pacific 13.2.2. By Therapy Type 13.2.3. By Disease Indication 13.2.4. By Animal Type 13.2.5. By Distribution Channel Type 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Therapy Type 13.3.3. By Disease Indication 13.3.4. By Animal Type 13.3.5. By Distribution Channel Type 13.4. Key Takeaways 14. Middle East and Africa Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2021 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of Middle East and Africa 14.2.2. By Therapy Type 14.2.3. By Disease Indication 14.2.4. By Animal Type 14.2.5. By Distribution Channel Type 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Therapy Type 14.3.3. By Disease Indication 14.3.4. By Animal Type 14.3.5. By Distribution Channel Type 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. United Kingdom 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2021 15.1.2.1. By Therapy Type 15.1.2.2. By Disease Indication 15.1.2.3. By Animal Type 15.1.2.4. By Distribution Channel Type 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2021 15.2.2.1. By Therapy Type 15.2.2.2. By Disease Indication 15.2.2.3. By Animal Type 15.2.2.4. By Distribution Channel Type 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2021 15.3.2.1. By Therapy Type 15.3.2.2. By Disease Indication 15.3.2.3. By Animal Type 15.3.2.4. By Distribution Channel Type 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2021 15.4.2.1. By Therapy Type 15.4.2.2. By Disease Indication 15.4.2.3. By Animal Type 15.4.2.4. By Distribution Channel Type 15.5. Rest of Latin America 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2021 15.5.2.1. By Therapy Type 15.5.2.2. By Disease Indication 15.5.2.3. By Animal Type 15.5.2.4. By Distribution Channel Type 15.6. Germany 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2021 15.6.2.1. By Therapy Type 15.6.2.2. By Disease Indication 15.6.2.3. By Animal Type 15.6.2.4. By Distribution Channel Type 15.7. United Kingdom 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2021 15.7.2.1. By Therapy Type 15.7.2.2. By Disease Indication 15.7.2.3. By Animal Type 15.7.2.4. By Distribution Channel Type 15.8. France 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2021 15.8.2.1. By Therapy Type 15.8.2.2. By Disease Indication 15.8.2.3. By Animal Type 15.8.2.4. By Distribution Channel Type 15.9. Spain 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2021 15.9.2.1. By Therapy Type 15.9.2.2. By Disease Indication 15.9.2.3. By Animal Type 15.9.2.4. By Distribution Channel Type 15.10. Italy 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2021 15.10.2.1. By Therapy Type 15.10.2.2. By Disease Indication 15.10.2.3. By Animal Type 15.10.2.4. By Distribution Channel Type 15.11. Rest of Europe 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2021 15.11.2.1. By Therapy Type 15.11.2.2. By Disease Indication 15.11.2.3. By Animal Type 15.11.2.4. By Distribution Channel Type 15.12. China 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2021 15.12.2.1. By Therapy Type 15.12.2.2. By Disease Indication 15.12.2.3. By Animal Type 15.12.2.4. By Distribution Channel Type 15.13. Japan 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2021 15.13.2.1. By Therapy Type 15.13.2.2. By Disease Indication 15.13.2.3. By Animal Type 15.13.2.4. By Distribution Channel Type 15.14. South Korea 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2021 15.14.2.1. By Therapy Type 15.14.2.2. By Disease Indication 15.14.2.3. By Animal Type 15.14.2.4. By Distribution Channel Type 15.15. Malaysia 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2021 15.15.2.1. By Therapy Type 15.15.2.2. By Disease Indication 15.15.2.3. By Animal Type 15.15.2.4. By Distribution Channel Type 15.16. Singapore 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2021 15.16.2.1. By Therapy Type 15.16.2.2. By Disease Indication 15.16.2.3. By Animal Type 15.16.2.4. By Distribution Channel Type 15.17. Australia 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2021 15.17.2.1. By Therapy Type 15.17.2.2. By Disease Indication 15.17.2.3. By Animal Type 15.17.2.4. By Distribution Channel Type 15.18. Rest of Asia Pacific 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2021 15.18.2.1. By Therapy Type 15.18.2.2. By Disease Indication 15.18.2.3. By Animal Type 15.18.2.4. By Distribution Channel Type 15.19. GCC Countries 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2021 15.19.2.1. By Therapy Type 15.19.2.2. By Disease Indication 15.19.2.3. By Animal Type 15.19.2.4. By Distribution Channel Type 15.20. South Africa 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2021 15.20.2.1. By Therapy Type 15.20.2.2. By Disease Indication 15.20.2.3. By Animal Type 15.20.2.4. By Distribution Channel Type 15.21. Israel 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2021 15.21.2.1. By Therapy Type 15.21.2.2. By Disease Indication 15.21.2.3. By Animal Type 15.21.2.4. By Distribution Channel Type 15.22. Rest of the Middle East and Africa 15.22.1. Pricing Analysis 15.22.2. Market Share Analysis, 2021 15.22.2.1. By Therapy Type 15.22.2.2. By Disease Indication 15.22.2.3. By Animal Type 15.22.2.4. By Distribution Channel Type 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Therapy Type 16.3.3. By Disease Indication 16.3.4. By Animal Type 16.3.5. By Distribution Channel Type 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Aratana Therapeutics Inc 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. Pfizer Inc 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. Vet-Stem, Inc 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. Ambrx Inc 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. Taconic Biosciences, Inc 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. JBS Value (US$ Million)ed 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. Virbac 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. Eli Lilly 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. Jaguar Animal Health Inc 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Customize this Report
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Global Market Value (US$ Million) Forecast by Region, 2017 to 2032 Table 02: Global Market Value (US$ Million) Forecast by Therapy Type, 2017 to 2032 Table 03: Global Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2032 Table 04: Global Market Value (US$ Million) Forecast by Animal Type, 2017 to 2032 Table 05: Global Market Value (US$ Million) Forecast by Distribution Channel Type, 2017 to 2032 Table 06: North America Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 07: North America Market Value (US$ Million) Forecast by Therapy Type, 2017 to 2032 Table 08: North America Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2032 Table 09: North America Market Value (US$ Million) Forecast by Animal Type, 2017 to 2032 Table 10: North America Market Value (US$ Million) Forecast by Distribution Channel Type, 2017 to 2032 Table 11: Latin America Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 12: Latin America Market Value (US$ Million) Forecast by Therapy Type, 2017 to 2032 Table 13: Latin America Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2032 Table 14: Latin America Market Value (US$ Million) Forecast by Animal Type, 2017 to 2032 Table 15: Latin America Market Value (US$ Million) Forecast by Distribution Channel Type, 2017 to 2032 Table 16: Europe Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 17: Europe Market Value (US$ Million) Forecast by Therapy Type, 2017 to 2032 Table 18: Europe Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2032 Table 19: Europe Market Value (US$ Million) Forecast by Animal Type, 2017 to 2032 Table 20: Europe Market Value (US$ Million) Forecast by Distribution Channel Type, 2017 to 2032 Table 21: Asia Pacific Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 22: Asia Pacific Market Value (US$ Million) Forecast by Therapy Type, 2017 to 2032 Table 23: Asia Pacific Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2032 Table 24: Asia Pacific Market Value (US$ Million) Forecast by Animal Type, 2017 to 2032 Table 25: Asia Pacific Market Value (US$ Million) Forecast by Distribution Channel Type, 2017 to 2032 Table 26: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2017 to 2032 Table 27: Middle East and Africa Market Value (US$ Million) Forecast by Therapy Type, 2017 to 2032 Table 28: Middle East and Africa Market Value (US$ Million) Forecast by Disease Indication, 2017 to 2032 Table 29: Middle East and Africa Market Value (US$ Million) Forecast by Animal Type, 2017 to 2032 Table 30: Middle East and Africa Market Value (US$ Million) Forecast by Distribution Channel Type, 2017 to 2032
Sabyasachi Ghosh
Principal Consultant
Talk to Analyst
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Global Market Value (US$ Million) by Therapy Type, 2022 to 2032 Figure 02: Global Market Value (US$ Million) by Disease Indication, 2022 to 2032 Figure 03: Global Market Value (US$ Million) by Animal Type, 2022 to 2032 Figure 04: Global Market Value (US$ Million) by Distribution Channel Type, 2022 to 2032 Figure 05: Global Market Value (US$ Million) by Region, 2022 to 2032 Figure 06: Global Market Value (US$ Million) Analysis by Region, 2017 to 2032 Figure 07: Global Market Value Share (%) and BPS Analysis by Region, 2022 to 2032 Figure 08: Global Market Y-o-Y Growth (%) Projections by Region, 2022 to 2032 Figure 09: Global Market Value (US$ Million) Analysis by Therapy Type, 2017 to 2032 Figure 10: Global Market Value Share (%) and BPS Analysis by Therapy Type, 2022 to 2032 Figure 11: Global Market Y-o-Y Growth (%) Projections by Therapy Type, 2022 to 2032 Figure 12: Global Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2032 Figure 13: Global Market Value Share (%) and BPS Analysis by Disease Indication, 2022 to 2032 Figure 14: Global Market Y-o-Y Growth (%) Projections by Disease Indication, 2022 to 2032 Figure 15: Global Market Value (US$ Million) Analysis by Animal Type, 2017 to 2032 Figure 16: Global Market Value Share (%) and BPS Analysis by Animal Type, 2022 to 2032 Figure 17: Global Market Y-o-Y Growth (%) Projections by Animal Type, 2022 to 2032 Figure 18: Global Market Value (US$ Million) Analysis by Distribution Channel Type, 2017 to 2032 Figure 19: Global Market Value Share (%) and BPS Analysis by Distribution Channel Type, 2022 to 2032 Figure 20: Global Market Y-o-Y Growth (%) Projections by Distribution Channel Type, 2022 to 2032 Figure 21: Global Market Attractiveness by Therapy Type, 2022 to 2032 Figure 22: Global Market Attractiveness by Disease Indication, 2022 to 2032 Figure 23: Global Market Attractiveness by Animal Type, 2022 to 2032 Figure 24: Global Market Attractiveness by Distribution Channel Type, 2022 to 2032 Figure 25: Global Market Attractiveness by Region, 2022 to 2032 Figure 26: North America Market Value (US$ Million) by Therapy Type, 2022 to 2032 Figure 27: North America Market Value (US$ Million) by Disease Indication, 2022 to 2032 Figure 28: North America Market Value (US$ Million) by Animal Type, 2022 to 2032 Figure 29: North America Market Value (US$ Million) by Distribution Channel Type, 2022 to 2032 Figure 30: North America Market Value (US$ Million) by Country, 2022 to 2032 Figure 31: North America Market Value (US$ Million) Analysis by Country, 2017 to 2032 Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 34: North America Market Value (US$ Million) Analysis by Therapy Type, 2017 to 2032 Figure 35: North America Market Value Share (%) and BPS Analysis by Therapy Type, 2022 to 2032 Figure 36: North America Market Y-o-Y Growth (%) Projections by Therapy Type, 2022 to 2032 Figure 37: North America Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2032 Figure 38: North America Market Value Share (%) and BPS Analysis by Disease Indication, 2022 to 2032 Figure 39: North America Market Y-o-Y Growth (%) Projections by Disease Indication, 2022 to 2032 Figure 40: North America Market Value (US$ Million) Analysis by Animal Type, 2017 to 2032 Figure 41: North America Market Value Share (%) and BPS Analysis by Animal Type, 2022 to 2032 Figure 42: North America Market Y-o-Y Growth (%) Projections by Animal Type, 2022 to 2032 Figure 43: North America Market Value (US$ Million) Analysis by Distribution Channel Type, 2017 to 2032 Figure 44: North America Market Value Share (%) and BPS Analysis by Distribution Channel Type, 2022 to 2032 Figure 45: North America Market Y-o-Y Growth (%) Projections by Distribution Channel Type, 2022 to 2032 Figure 46: North America Market Attractiveness by Therapy Type, 2022 to 2032 Figure 47: North America Market Attractiveness by Disease Indication, 2022 to 2032 Figure 48: North America Market Attractiveness by Animal Type, 2022 to 2032 Figure 49: North America Market Attractiveness by Distribution Channel Type, 2022 to 2032 Figure 50: North America Market Attractiveness by Country, 2022 to 2032 Figure 51: Latin America Market Value (US$ Million) by Therapy Type, 2022 to 2032 Figure 52: Latin America Market Value (US$ Million) by Disease Indication, 2022 to 2032 Figure 53: Latin America Market Value (US$ Million) by Animal Type, 2022 to 2032 Figure 54: Latin America Market Value (US$ Million) by Distribution Channel Type, 2022 to 2032 Figure 55: Latin America Market Value (US$ Million) by Country, 2022 to 2032 Figure 56: Latin America Market Value (US$ Million) Analysis by Country, 2017 to 2032 Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 59: Latin America Market Value (US$ Million) Analysis by Therapy Type, 2017 to 2032 Figure 60: Latin America Market Value Share (%) and BPS Analysis by Therapy Type, 2022 to 2032 Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Therapy Type, 2022 to 2032 Figure 62: Latin America Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2032 Figure 63: Latin America Market Value Share (%) and BPS Analysis by Disease Indication, 2022 to 2032 Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Disease Indication, 2022 to 2032 Figure 65: Latin America Market Value (US$ Million) Analysis by Animal Type, 2017 to 2032 Figure 66: Latin America Market Value Share (%) and BPS Analysis by Animal Type, 2022 to 2032 Figure 67: Latin America Market Y-o-Y Growth (%) Projections by Animal Type, 2022 to 2032 Figure 68: Latin America Market Value (US$ Million) Analysis by Distribution Channel Type, 2017 to 2032 Figure 69: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel Type, 2022 to 2032 Figure 70: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel Type, 2022 to 2032 Figure 71: Latin America Market Attractiveness by Therapy Type, 2022 to 2032 Figure 72: Latin America Market Attractiveness by Disease Indication, 2022 to 2032 Figure 73: Latin America Market Attractiveness by Animal Type, 2022 to 2032 Figure 74: Latin America Market Attractiveness by Distribution Channel Type, 2022 to 2032 Figure 75: Latin America Market Attractiveness by Country, 2022 to 2032 Figure 76: Europe Market Value (US$ Million) by Therapy Type, 2022 to 2032 Figure 77: Europe Market Value (US$ Million) by Disease Indication, 2022 to 2032 Figure 78: Europe Market Value (US$ Million) by Animal Type, 2022 to 2032 Figure 79: Europe Market Value (US$ Million) by Distribution Channel Type, 2022 to 2032 Figure 80: Europe Market Value (US$ Million) by Country, 2022 to 2032 Figure 81: Europe Market Value (US$ Million) Analysis by Country, 2017 to 2032 Figure 82: Europe Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 83: Europe Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 84: Europe Market Value (US$ Million) Analysis by Therapy Type, 2017 to 2032 Figure 85: Europe Market Value Share (%) and BPS Analysis by Therapy Type, 2022 to 2032 Figure 86: Europe Market Y-o-Y Growth (%) Projections by Therapy Type, 2022 to 2032 Figure 87: Europe Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2032 Figure 88: Europe Market Value Share (%) and BPS Analysis by Disease Indication, 2022 to 2032 Figure 89: Europe Market Y-o-Y Growth (%) Projections by Disease Indication, 2022 to 2032 Figure 90: Europe Market Value (US$ Million) Analysis by Animal Type, 2017 to 2032 Figure 91: Europe Market Value Share (%) and BPS Analysis by Animal Type, 2022 to 2032 Figure 92: Europe Market Y-o-Y Growth (%) Projections by Animal Type, 2022 to 2032 Figure 93: Europe Market Value (US$ Million) Analysis by Distribution Channel Type, 2017 to 2032 Figure 94: Europe Market Value Share (%) and BPS Analysis by Distribution Channel Type, 2022 to 2032 Figure 95: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel Type, 2022 to 2032 Figure 96: Europe Market Attractiveness by Therapy Type, 2022 to 2032 Figure 97: Europe Market Attractiveness by Disease Indication, 2022 to 2032 Figure 98: Europe Market Attractiveness by Animal Type, 2022 to 2032 Figure 99: Europe Market Attractiveness by Distribution Channel Type, 2022 to 2032 Figure 100: Europe Market Attractiveness by Country, 2022 to 2032 Figure 101: Asia Pacific Market Value (US$ Million) by Therapy Type, 2022 to 2032 Figure 102: Asia Pacific Market Value (US$ Million) by Disease Indication, 2022 to 2032 Figure 103: Asia Pacific Market Value (US$ Million) by Animal Type, 2022 to 2032 Figure 104: Asia Pacific Market Value (US$ Million) by Distribution Channel Type, 2022 to 2032 Figure 105: Asia Pacific Market Value (US$ Million) by Country, 2022 to 2032 Figure 106: Asia Pacific Market Value (US$ Million) Analysis by Country, 2017 to 2032 Figure 107: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 108: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 109: Asia Pacific Market Value (US$ Million) Analysis by Therapy Type, 2017 to 2032 Figure 110: Asia Pacific Market Value Share (%) and BPS Analysis by Therapy Type, 2022 to 2032 Figure 111: Asia Pacific Market Y-o-Y Growth (%) Projections by Therapy Type, 2022 to 2032 Figure 112: Asia Pacific Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2032 Figure 113: Asia Pacific Market Value Share (%) and BPS Analysis by Disease Indication, 2022 to 2032 Figure 114: Asia Pacific Market Y-o-Y Growth (%) Projections by Disease Indication, 2022 to 2032 Figure 115: Asia Pacific Market Value (US$ Million) Analysis by Animal Type, 2017 to 2032 Figure 116: Asia Pacific Market Value Share (%) and BPS Analysis by Animal Type, 2022 to 2032 Figure 117: Asia Pacific Market Y-o-Y Growth (%) Projections by Animal Type, 2022 to 2032 Figure 118: Asia Pacific Market Value (US$ Million) Analysis by Distribution Channel Type, 2017 to 2032 Figure 119: Asia Pacific Market Value Share (%) and BPS Analysis by Distribution Channel Type, 2022 to 2032 Figure 120: Asia Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel Type, 2022 to 2032 Figure 121: Asia Pacific Market Attractiveness by Therapy Type, 2022 to 2032 Figure 122: Asia Pacific Market Attractiveness by Disease Indication, 2022 to 2032 Figure 123: Asia Pacific Market Attractiveness by Animal Type, 2022 to 2032 Figure 124: Asia Pacific Market Attractiveness by Distribution Channel Type, 2022 to 2032 Figure 125: Asia Pacific Market Attractiveness by Country, 2022 to 2032 Figure 126: Middle East and Africa Market Value (US$ Million) by Therapy Type, 2022 to 2032 Figure 127: Middle East and Africa Market Value (US$ Million) by Disease Indication, 2022 to 2032 Figure 128: Middle East and Africa Market Value (US$ Million) by Animal Type, 2022 to 2032 Figure 129: Middle East and Africa Market Value (US$ Million) by Distribution Channel Type, 2022 to 2032 Figure 130: Middle East and Africa Market Value (US$ Million) by Country, 2022 to 2032 Figure 131: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2017 to 2032 Figure 132: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2022 to 2032 Figure 133: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032 Figure 134: Middle East and Africa Market Value (US$ Million) Analysis by Therapy Type, 2017 to 2032 Figure 135: Middle East and Africa Market Value Share (%) and BPS Analysis by Therapy Type, 2022 to 2032 Figure 136: Middle East and Africa Market Y-o-Y Growth (%) Projections by Therapy Type, 2022 to 2032 Figure 137: Middle East and Africa Market Value (US$ Million) Analysis by Disease Indication, 2017 to 2032 Figure 138: Middle East and Africa Market Value Share (%) and BPS Analysis by Disease Indication, 2022 to 2032 Figure 139: Middle East and Africa Market Y-o-Y Growth (%) Projections by Disease Indication, 2022 to 2032 Figure 140: Middle East and Africa Market Value (US$ Million) Analysis by Animal Type, 2017 to 2032 Figure 141: Middle East and Africa Market Value Share (%) and BPS Analysis by Animal Type, 2022 to 2032 Figure 142: Middle East and Africa Market Y-o-Y Growth (%) Projections by Animal Type, 2022 to 2032 Figure 143: Middle East and Africa Market Value (US$ Million) Analysis by Distribution Channel Type, 2017 to 2032 Figure 144: Middle East and Africa Market Value Share (%) and BPS Analysis by Distribution Channel Type, 2022 to 2032 Figure 145: Middle East and Africa Market Y-o-Y Growth (%) Projections by Distribution Channel Type, 2022 to 2032 Figure 146: Middle East and Africa Market Attractiveness by Therapy Type, 2022 to 2032 Figure 147: Middle East and Africa Market Attractiveness by Disease Indication, 2022 to 2032 Figure 148: Middle East and Africa Market Attractiveness by Animal Type, 2022 to 2032 Figure 149: Middle East and Africa Market Attractiveness by Distribution Channel Type, 2022 to 2032 Figure 150: Middle East and Africa Market Attractiveness by Country, 2022 to 2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
